231 related articles for article (PubMed ID: 9479058)
1. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.
Beal MF; Matthews RT; Tieleman A; Shults CW
Brain Res; 1998 Feb; 783(1):109-14. PubMed ID: 9479058
[TBL] [Abstract][Full Text] [Related]
2. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice.
Date I; Felten SY; Felten DL
Neurosci Lett; 1989 Dec; 106(3):282-6. PubMed ID: 2601883
[TBL] [Abstract][Full Text] [Related]
3. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism.
Cleren C; Yang L; Lorenzo B; Calingasan NY; Schomer A; Sireci A; Wille EJ; Beal MF
J Neurochem; 2008 Mar; 104(6):1613-21. PubMed ID: 17973981
[TBL] [Abstract][Full Text] [Related]
5. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging.
Date I; Yoshimoto Y; Imaoka T; Miyoshi Y; Gohda Y; Furuta T; Asari S; Ohmoto T
Brain Res; 1993 Sep; 621(1):150-4. PubMed ID: 8106113
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
7. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
Nishi K
Brain Res; 1997 Oct; 771(1):133-41. PubMed ID: 9383016
[TBL] [Abstract][Full Text] [Related]
9. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
10. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
[TBL] [Abstract][Full Text] [Related]
11. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
12. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
13. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
14. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Imai Y; Kato H; Araki T
Neurol Res; 2004 Sep; 26(6):644-57. PubMed ID: 15327754
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Oeckl P; Ferger B
Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
[TBL] [Abstract][Full Text] [Related]
17. MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).
Date I; Notter MF; Felten SY; Felten DL
Brain Res; 1990 Aug; 526(1):156-60. PubMed ID: 1706636
[TBL] [Abstract][Full Text] [Related]
18. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
20. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
Tanji H; Araki T; Nagasawa H; Itoyama Y
Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
